Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for vTv Therapeutics Inc. (VTVT : NSDQ)
 
 • Company Description   
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Number of Employees: 23

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.06 Daily Weekly Monthly
20 Day Moving Average: 7,755 shares
Shares Outstanding: 3.19 (millions)
Market Capitalization: $48.11 (millions)
Beta: 0.58
52 Week High: $26.99
52 Week Low: $12.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.88% -9.75%
12 Week -18.73% -28.78%
Year To Date 9.06% 3.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3980 PREMIER DR SUITE 310
-
HIGH POINT,NC 27265
USA
ph: 336-841-0300
fax: 336-841-0310
ir@vtvtherapeutics.com http://www.vtvtherapeutics.com
 
 • General Corporate Information   
Officers
Paul J. Sekhri - President; Chief Executive Officer and Executive C
Steven Tuch - Executive Vice President and Chief Financial Offic
Richard Nelson - Director and Executive Vice President; Corporate D
Anne M. Phillips - Director
Daniel K. Spiegelman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 918385204
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 3.19
Most Recent Split Date: 11.00 (0.03:1)
Beta: 0.58
Market Capitalization: $48.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.40
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 34.19%
vs. Previous Quarter: -40.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -121.46
12/31/24 - -93.91
ROA
06/30/25 - -
03/31/25 - -46.75
12/31/24 - -40.56
Current Ratio
06/30/25 - -
03/31/25 - 7.39
12/31/24 - 7.34
Quick Ratio
06/30/25 - -
03/31/25 - 7.39
12/31/24 - 7.34
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -134,723.52
12/31/24 - -2,222.71
Book Value
06/30/25 - -
03/31/25 - 2.79
12/31/24 - 4.48
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©